CD4 and leukemia: Therefore, despite some limitations, the present study demonstrates that modified LEXs can directly target CD4+ T cells, making CD4+ TLEX-CD8086 cells a potent anti-leukemia vaccine with multiple antigen targets and providing a new EXO-based vaccine strategy for induction of immune responses against tumors and other infectious diseases.